Clinical trial
A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03029455 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- August 31, 2017
- Enrollment
- 163 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.